Skip to content
HCN Grants Est. 2026
No. HT942526BCRPBTA3 · Defense Health Agency Contracting Activity - DHACA
Open

DoW Breast Cancer, Breakthrough Award Level 3

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“Invitation to Submit an Application: July 16, 2026” — From the announcement

At a glance

This program funds advanced translational breast cancer research under the FY26 Breast Cancer Research Program, with small-scale clinical trials allowed but not required. Applicants must address at least one FY26 breast cancer challenge unless they provide an approved justification, and each project must include two or more breast cancer consumer advocates. Eligible applicants include U.S. Department of War intramural and extramural organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities; awards are made to organizations, not individuals. The program expects to fund about two awards, with total cost caps of $5.6 million for a single PI or $7.0 million for the partnering PI option, over a maximum period of four years. Cost sharing is not required.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3. Distinctive Features: · For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide